Adalimumab biosimilar - Sandoz

Drug Profile

Adalimumab biosimilar - Sandoz

Alternative Names: GP-2017

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sandoz
  • Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antipsoriatics; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Immunomodulators; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Plaque psoriasis
  • Phase III Rheumatoid arthritis

Most Recent Events

  • 14 Sep 2017 Updated efficacy and immunogenicity data from the phase III ADACCESS trial in Plaque psoriasis released by Sandoz
  • 31 Aug 2017 Novartis plans the SURPASS phase III trial for Ankylosing spondylitis (NCT03259074)
  • 31 May 2017 Preregistration for Plaque psoriasis in European Union before May 2017 (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top